Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : NEW BREAST IMPLANT FOR PATIENTS UNDERGOING BREAST RECONSTRUCTION, AUGMENTATION OR REVISION SURGERY

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 05:30pm CET

NEW BREAST IMPLANT FOR PATIENTS UNDERGOING BREAST RECONSTRUCTION, AUGMENTATION OR REVISION SURGERY

MENTOR® Announces U.S. Availability For MemoryGel® Xtra Breast Implants

Irvine, Calif., October 4, 2017 -- Mentor Worldwide LLC, a global leader in breast aesthetics, today announced the availability of its MemoryGel Xtra Breast Implants in the United States. MENTOR MemoryGel Xtra - which is being showcased at the 2017 Plastic Surgery Meeting hosted by the American Society of Plastic Surgeons (ASPS) in Orlando, FL (Johnson & Johnson Medical Devices Booth #523) - is the only breast implant on the market which allows for increased projection, fullness and firmnesswithout losing the soft, natural feel patients desire.

'I'm excited to provide my patients with the latest breast implant option from MENTOR,' said Dr Louis Strock*, American Board of Plastic Surgery, Diplomate. 'MemoryGel Xtra Breast Implants offer a rare combination of a more tight feel while maintaining an overall natural softness.'

In a recent blinded brand comparison, nine out of 10 consumers chose MemoryGel Xtra implants as feeling more like natural (or real) breasts. Surgeons also chose MemoryGel Xtra implants as a product they would use more often at their practice.

'For more than 30 years, approximately 5 million women have chosen MENTOR breast implants as a safe and reliable option to achieve their desired outcome,' said Dr. John Canady, Franchise Medical Leader, Johnson & Johnson Medical Devices. 'We're always looking for ways to advance our products and meet the ever-evolving needs of our patients. The meaningful innovation of MemoryGel Xtra not only increases options for patients but also reinforces the MENTOR global leadership position in breast aesthetics.'

MENTOR MemoryGel Xtra breast implants were approved by the U.S. Food & Drug Administration in April 2017.

MENTOR also recently launched the ARTOURA™ Breast Tissue Expander line with a smooth shell in July 2017 throughout the U.S. This new option provides an alternative for surgeons who may prefer a smooth tissue expander.

About Mentor Worldwide LLC

Mentor Worldwide LLC, part of Johnson & Johnson Medical Devices Companies, is a leading supplier of breast implants in the global aesthetic market. The company develops, manufactures, and markets innovative, science-based products for surgical and non-surgical medical procedures that allow breast surgery patients to improve their quality of life. The company is focused on two strategic areas: breast reconstruction and breast augmentation. MENTOR is the only manufacturer whose silicone breast implants are made in the U.S.A.
For more information about MENTOR visit: www.mentorwwllc.com

Important Safety Information:

MENTOR MemoryGel Breast Implants are indicated for breast augmentation in women at least 22 years old or for breast reconstruction. Breast implant surgery should not be performed in women with active infection anywhere in their body with existing cancer or pre-cancer of their breast who have not received adequate treatment for those conditions or are pregnant or nursing.

Breast implants are not lifetime devices and breast implantation is not necessarily a one-time surgery. The most common complications with the MemoryGel Breast Implants include reoperation, capsular contracture, asymmetry, and breast pain. A lower risk of complication is rupture. The health consequences of a ruptured silicone gel-filled breast implant have not been fully established. MRI screenings are recommended three years after initial implant surgery and then every two years after to detect silent rupture.

Patients should receive a copy of Important Information for Augmentation Patients about MENTORMemoryGel Silicone Gel-Filled Breast Implants or Important Information for Reconstruction Patients about MENTOR MemoryGel Silicone Gel-Filled Breast Implants. Your patient needs to read and understand the information regarding the risks and benefits of breast implants, with an opportunity to consult with you prior to deciding on surgery.

For detailed indications, contraindications, warning and precautions associated with the use of MemoryGel Breast Implants. Please refer to the Product Insert Data Sheet provided with each product, or online at www.mentorwwllc.com.

* Dr. Strock is a paid consultant to Mentor Worldwide LLC.1. When compared to MemoryGel Breast Implants
2. Product Dimensions for MemoryGel and MemoryGel Xtra Breast Implants
3. Mentor R&D Compression Benchtop Testing - July 2017
4. In-person consumer survey with 452 respondents. Mentor Consumer Preference Market Research Report - July 2017
5. Head-to-head blinded in-person tabletop product comparison (MemoryGel Xtra vs. Inspira Responsive vs. Inspira Cohesive) with 452 respondents
6. Head-to-head in-person tabletop product comparison (MemoryGel Xtra vs. Inspira Responsive vs. Inspira Cohesive) with 79 surgeons. Mentor Surgeon Preference Market Research Report - July 2017

###

Contact:
Emma Reynolds
(949) 562-2196
[email protected]

Johnson & Johnson published this content on 06 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 October 2017 15:29:02 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02:56a JOHNSON & JOHNSON : Youth schooled on HIV/AIDS prevention and non-discrimination
12/12 JOHNSON & JOHNSON : LSP closes second health economic fund at EUR 280M
12/12 JOHNSON & JOHNSON : DARZALEX® (daratumumab) Combination Regimen Significantly Im..
12/12 JOHNSON & JOHNSON : Motus GI Appoints Gary J. Pruden, Former Worldwide Chairman ..
12/12 JOHNSON & JOHNSON : Joins HIV Campaign
12/12 Sanofi investors hungry for drug progress and deal news
12/12 JOHNSON & JOHNSON : New Data for DARZALEX® (daratumumab) Presented at ASH 2017 S..
12/11 JOHNSON & JOHNSON : Sustained Benefit in Patients With Relapsed/Refractory Mantl..
12/11 JOHNSON & JOHNSON : How Johnson & Johnson is Helping Support Service Members Thr..
12/11 JOHNSON & JOHNSON : Wetherby Asset Management Holds Holding in Johnson & Johnson..
More news
News from SeekingAlpha
12/12 MCDONALD'S : Dividend Increase For Income And Good Total Return
12/12 Positive Market In 2017 - Cramer's Mad Money (12/11/17)
12/11 Johnson & Johnson files U.S. marketing application for expanded label use of ..
12/11 Where To Invest To Benefit From The Corporate Tax Cut
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,37%
P/E ratio 2017 23,66
P/E ratio 2018 19,47
EV / Sales 2017 5,19x
EV / Sales 2018 4,79x
Capitalization 379 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 146 $
Spread / Average Target 3,2%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659
AMGEN18.98%128 363